These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 24321374)

  • 1. Pharmacokinetics and safety of single doses of drisapersen in non-ambulant subjects with Duchenne muscular dystrophy: results of a double-blind randomized clinical trial.
    Flanigan KM; Voit T; Rosales XQ; Servais L; Kraus JE; Wardell C; Morgan A; Dorricott S; Nakielny J; Quarcoo N; Liefaard L; Drury T; Campion G; Wright P
    Neuromuscul Disord; 2014 Jan; 24(1):16-24. PubMed ID: 24321374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study.
    Goemans NM; Tulinius M; van den Hauwe M; Kroksmark AK; Buyse G; Wilson RJ; van Deutekom JC; de Kimpe SJ; Lourbakos A; Campion G
    PLoS One; 2016; 11(9):e0161955. PubMed ID: 27588424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy.
    Goemans N; Mercuri E; Belousova E; Komaki H; Dubrovsky A; McDonald CM; Kraus JE; Lourbakos A; Lin Z; Campion G; Wang SX; Campbell C;
    Neuromuscul Disord; 2018 Jan; 28(1):4-15. PubMed ID: 29203355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Injection site reactions after long-term subcutaneous delivery of drisapersen: a retrospective study.
    Hilhorst N; Spanoudi-Kitrimi I; Goemans N; Morren MA
    Eur J Pediatr; 2019 Feb; 178(2):253-258. PubMed ID: 30448867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study.
    Voit T; Topaloglu H; Straub V; Muntoni F; Deconinck N; Campion G; De Kimpe SJ; Eagle M; Guglieri M; Hood S; Liefaard L; Lourbakos A; Morgan A; Nakielny J; Quarcoo N; Ricotti V; Rolfe K; Servais L; Wardell C; Wilson R; Wright P; Kraus JE
    Lancet Neurol; 2014 Oct; 13(10):987-96. PubMed ID: 25209738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of ambulatory capacity and disease progression of Duchenne muscular dystrophy subjects enrolled in the drisapersen DMD114673 study with a matched natural history cohort of subjects on daily corticosteroids.
    Goemans N; Tulinius M; Kroksmark AK; Wilson R; van den Hauwe M; Campion G
    Neuromuscul Disord; 2017 Mar; 27(3):203-213. PubMed ID: 28169120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: A randomized, double-blind, placebo-controlled, dose-titration trial.
    Wagner KR; Kuntz NL; Koenig E; East L; Upadhyay S; Han B; Shieh PB
    Muscle Nerve; 2021 Sep; 64(3):285-292. PubMed ID: 34105177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exon skipping therapy for Duchenne muscular dystrophy.
    Kole R; Krieg AM
    Adv Drug Deliv Rev; 2015 Jun; 87():104-7. PubMed ID: 25980936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial.
    Clemens PR; Rao VK; Connolly AM; Harper AD; Mah JK; Smith EC; McDonald CM; Zaidman CM; Morgenroth LP; Osaki H; Satou Y; Yamashita T; Hoffman EP;
    JAMA Neurol; 2020 Aug; 77(8):982-991. PubMed ID: 32453377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exon skipping for Duchenne muscular dystrophy: a systematic review and meta-analysis.
    Shimizu-Motohashi Y; Murakami T; Kimura E; Komaki H; Watanabe N
    Orphanet J Rare Dis; 2018 Jun; 13(1):93. PubMed ID: 29907124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PRO-051, an antisense oligonucleotide for the potential treatment of Duchenne muscular dystrophy.
    Hammond SM; Wood MJ
    Curr Opin Mol Ther; 2010 Aug; 12(4):478-86. PubMed ID: 20677099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Viltolarsen for the treatment of Duchenne muscular dystrophy.
    Roshmi RR; Yokota T
    Drugs Today (Barc); 2019 Oct; 55(10):627-639. PubMed ID: 31720560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Golodirsen for Duchenne muscular dystrophy.
    Anwar S; Yokota T
    Drugs Today (Barc); 2020 Aug; 56(8):491-504. PubMed ID: 33025945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic administration of the antisense oligonucleotide NS-065/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy.
    Komaki H; Nagata T; Saito T; Masuda S; Takeshita E; Sasaki M; Tachimori H; Nakamura H; Aoki Y; Takeda S
    Sci Transl Med; 2018 Apr; 10(437):. PubMed ID: 29669851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
    Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
    Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viltolarsen in Japanese Duchenne muscular dystrophy patients: A phase 1/2 study.
    Komaki H; Takeshima Y; Matsumura T; Ozasa S; Funato M; Takeshita E; Iwata Y; Yajima H; Egawa Y; Toramoto T; Tajima M; Takeda S
    Ann Clin Transl Neurol; 2020 Dec; 7(12):2393-2408. PubMed ID: 33285037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, tolerability and pharmacokinetics of eteplirsen in young boys aged 6-48 months with Duchenne muscular dystrophy amenable to exon 51 skipping.
    Mercuri E; Seferian AM; Servais L; Deconinck N; Stevenson H; Ni X; Zhang W; East L; Yonren S; Muntoni F;
    Neuromuscul Disord; 2023 Jun; 33(6):476-483. PubMed ID: 37207382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonclinical Exon Skipping Studies with 2'-O-Methyl Phosphorothioate Antisense Oligonucleotides in mdx and mdx-utrn-/- Mice Inspired by Clinical Trial Results.
    van Putten M; Tanganyika-de Winter C; Bosgra S; Aartsma-Rus A
    Nucleic Acid Ther; 2019 Apr; 29(2):92-103. PubMed ID: 30672725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Placebo-controlled Phase 2 Trial of Drisapersen for Duchenne Muscular Dystrophy.
    McDonald CM; Wong B; Flanigan KM; Wilson R; de Kimpe S; Lourbakos A; Lin Z; Campion G;
    Ann Clin Transl Neurol; 2018 Aug; 5(8):913-926. PubMed ID: 30128316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Restorative treatments of dystrophin expression in Duchenne muscular dystrophy: A systematic review.
    Pascual-Morena C; Cavero-Redondo I; Álvarez-Bueno C; Mesas AE; Pozuelo-Carrascosa D; Martínez-Vizcaíno V
    Ann Clin Transl Neurol; 2020 Sep; 7(9):1738-1752. PubMed ID: 33325654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.